Skip to content

Cytokine adsorption therapy for pulmonary tuberculosis complicated with respiratory failure and sepsis

A new comprehensive treatment strategy based on cytokine adsorption for pulmonary tuberculosis complicated with respiratory failure and sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082529
Enrollment
Unknown
Registered
2024-04-01
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary tuberculosis and sepsis

Interventions

Experimental group:Cytokine adsorption therapy+conventional treatment
Control group:Conventional treatment

Sponsors

Guangzhou Chest Hospital (tuberculosis Prevention and Control Institute, tuberculosis Treatment Center)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age range from 18 to 75 years old; Meets the following three criteria: ? Confirmed pulmonary tuberculosis patients: Diagnosis and Treatment Guidelines for Pulmonary Tuberculosis (2013 Edition); ? Respiratory failure: in accordance with the Clinical Guidelines for Mechanical Ventilation (2006); ? Sepsis: 2016 Sepsis 3.0 standard: presence of infection with two or more of the following symptoms: body temperature>38.3 ° C or90 beats per minute; Rapid breathing>20 beats per minute or arterial partial pressure of carbon dioxide (PaCO 2)7.7 mmol/L [>140 mg/dL]); Acute changes in consciousness state; Increased white blood cells (white blood cell, WBC count>12) × 10 ?/L [12000/ µ L] ); Decreased white blood cells (WBC count10%.

Exclusion criteria

Exclusion criteria: Pregnant women with respiratory failure induced by bronchial asthma, common obstructive airway diseases (such as COPD), bronchiectasis, severe heart disease, and contraindications to mechanical ventilation.

Design outcomes

Primary

MeasureTime frame
28 day survival rate; ICU ICU survival rate;

Secondary

MeasureTime frame
Hemodynamic parameters (dose of vasopressor);72 hour post body fluid balance and pre - and post intervention organ failure assessment score (SOFA);

Countries

China

Contacts

Public ContactHu Jinxing

Guangzhou Chest Hospital (tuberculosis Prevention and Control Institute, tuberculosis Treatment Center)

hujinxing2000@163.com+86 136 3146 7028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026